Cohance Lifesciences has announced a USD 10 million (approximately Rs. 83 crore) investment into its United States subsidiary, marking a strategic push to strengthen its footprint in the world’s largest pharmaceutical market. The infusion of capital will be directed toward enhancing manufacturing capabilities, scaling research and development, and expanding product portfolios in niche therapeutic categories. This move underscores Cohance’s commitment to global growth, leveraging its expertise in contract development and manufacturing services (CDMO).